Zealand Pharma A/S ADR (ZEAL) Stock
ZEAL is no longer traded. Zealand Pharma A/S ADR was delisted from the Nasdaq in September 2022.
Prices on this page are historical; the last trade was September 29, 2022 at $17.59.
Zealand Pharma A/S ADR stock price history
ZEAL final trading statistics
- Final close
- $17.59
- Final trading day
- Sep 29, 2022
- Market cap at delisting
- $811.25M
- Shares outstanding
- 46.12M
- Final 52-week range
- $9.93 – $32.94
- Avg. volume (final 3 mo.)
- 2,447
- All-time high (split-adj.)
- $44.25 · Feb 2020
- All-time low (split-adj.)
- $10.05 · May 2022
- Return since IPO
- -1.3%
- Beta
- 1.34
- Book value / share
- $10.91
- Price / book
- 1.61
Zealand Pharma A/S ADR annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2021 | $292.57M | -$1.0B | -$23.75 |
| FY2020 | $353.31M | -$846.7M | -$22.07 |
| FY2019 | $41.33M | -$571.5M | -$16.91 |
| FY2018 | $37.98M | $581.3M | $24.99 |
| FY2017 | $139.78M | -$272.3M | -$1.76 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Zealand Pharma A/S ADR
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Zealand Pharma A/S ADR stock FAQ
What happened to Zealand Pharma A/S ADR stock?
Zealand Pharma A/S ADR stock was delisted from the Nasdaq. Its final close was $17.59 on September 29, 2022.
Is ZEAL stock still trading?
No. ZEAL was delisted from the Nasdaq in September 2022 and no longer trades on a U.S. exchange.
What was the last price of ZEAL stock?
ZEAL closed at $17.59 on its final trading day, September 29, 2022, for a market value of about $811.25M.
What were Zealand Pharma A/S ADR's revenue and earnings in its last full fiscal year?
Zealand Pharma A/S ADR reported revenue of $292.57M and net income of -$1.0B in fiscal 2021, its last full year as a public company.
When did Zealand Pharma A/S ADR go public?
Zealand Pharma A/S ADR stock began trading on August 9, 2017.